Evaluation of Antioxidant and Immunity Function of Tetramethylpyrazine Phosphate Tablets in Vivo
Abstract
:1. Introduction
2. Results
Group | Left ventricular end diastolic pressure (mmHg) | Left ventricular systolic pressure (mmHg) | +dp/dtmax (mmHg/s) | −dp/dtmax (mmHg/s) |
---|---|---|---|---|
Normal | 5.61 ± 0.36 | 118.32 ± 12.09 | 3215.85 ± 276.83 | 3064.44 ± 274.13 |
ISO model | 11.07 ± 0.96 ** | 99.26 ± 6.73 ** | 2087.59 ± 187.36 ** | 2007.46 ± 184.07 ** |
TPT+ISO (2 mg/kg) | 8.21 ± 0.74 ## | 105.32 ± 8.64 | 2548.65 ± 215.73 ## | 2316.49 ± 198.67 ## |
TPT+ISO (3 mg/kg) | 7.05 ± 0.63 ## | 107.43 ± 5.93 | 2749.06 ± 251.16 ## | 2781.77 ± 201.74 ## |
TPT+ISO (4 mg/kg) | 6.11 ± 0.54 ## | 113.65 ± 7.07 # | 3081.16 ± 255.78 ## | 2991.83 ± 222.69 ## |
Group | LVMI (mg/g) | RVMI (mg/g) |
---|---|---|
Normal | 2.31 ± 0.22 | 0.65 ± 0.05 |
ISO model | 3.57 ± 0.27 ** | 0.77 ± 0.05 ** |
TPT+ISO (2 mg/kg) | 3.21 ± 0.24 # | 0.73 ± 0.06 |
TPT+ISO (3 mg/kg) | 2.89 ± 0.21 ## | 0.69 ± 0.05 # |
TPT+ISO (4 mg/kg) | 2.53 ± 0.23 ## | 0.66 ± 0.06 # |
Group | Ang II (pg/mL) | Cholesterol (ng/mL) | ANP (ng/mL) | Endothelin (pg/mL) |
---|---|---|---|---|
Normal | 1408.32 ± 112.73 | 0.605 ± 0.046 | 0.687 ± 0.048 | 161.52 ± 11.75 |
ISO model | 1676.81 ± 140.27 ** | 1.241 ± 0.094 ** | 1.085 ± 0.088 ** | 219.04 ± 15.48 ** |
TPT+ISO (2 mg/kg) | 1582.09 ± 121.53 # | 1.042 ± 0.082 ## | 0.913 ± 0.073 ## | 201.16 ± 18.04 # |
TPT+ISO (3 mg/kg) | 1503.17 ± 131.64 ## | 0.831 ± 0.067 ## | 0.831 ± 0.065 ## | 188.42 ± 15.83 ## |
TPT+ISO (4 mg/kg) | 1437.83 ± 133.29 ## | 0.683 ± 0.049 ## | 0.715 ± 0.069 ## | 170.47 ± 14.92 ## |
Group | TNF-α (ng/L) | IL-6 (ng/L) |
---|---|---|
Normal | 61.74 ± 4.83 | 111.64 ± 10.75 |
ISO model | 174.27 ± 12.15 ** | 241.47 ± 14.28 ** |
TPT+ISO (2 mg/kg) | 142.68 ± 11.09 ## | 203.62 ± 12.63 ## |
TPT+ISO (3 mg/kg) | 101.23 ± 7.69 ## | 175.39 ± 11.49 ## |
TPT+ISO (4 mg/kg) | 75.29 ± 4.62 ## | 136.18 ± 9.75 ## |
Group | MDA | GSH | SOD | CAT | GSH-Px |
---|---|---|---|---|---|
Normal | 4.05 ± 0.25 | 132.7 ± 12.6 | 254.4 ± 32.8 | 35.13 ± 2.96 | 42.71 ± 3.09 |
ISO model | 7.49 ± 0.53 ** | 78.4 ± 4.6 ** | 127.3 ± 10.9 ** | 13.29 ± 1.76 ** | 21.69 ± 1.57 ** |
TPT+ISO (2 mg/kg) | 6.11 ± 0.47 ## | 94.1 ± 4.7 ## | 164.8 ± 15.5 ## | 18.95 ± 1.49 ## | 28.46 ± 1.63 ## |
TPT+ISO (3 mg/kg) | 5.24 ± 0.32 ## | 115.7 ± 10.7 ## | 199.2 ± 20.8 ## | 25.75 ± 1.83 ## | 36.92 ± 1.71 ## |
TPT+ISO (4 mg/kg) | 4.32 ± 0.24 ## | 142.6 ± 13.1 ## | 248.1 ± 23.1 ## | 33.86 ± 2.07 ## | 40.62 ± 2.69 ## |
3. Discussion
4. Experimental
4.1. Materials
4.2. Animal
4.3. Experimental Design
4.4. Hemodynamic Assessment
4.5. Biochemical Analysis
4.6. Histopathological Examination
4.7. Statistical Analysis
5. Conclusion
Acknowledgements
- Sample Availability: Samples of the compounds are available from the local medicine shop.
Reference and Notes
- Fang, J.; Mensah, G.A.; Croft, J.B.; Keenan, N.L. Heart failure-related hospitalization in the U.S., 1979 to 2004. J. Am. Coll. Cardiol. 2008, 52, 428–434. [Google Scholar]
- Parissis, J.T.; Fountoulaki, K.; Paraskevaidis, I.; Kremastinos, D. Depression in chronic heart failure: Novel pathophysiological mechanisms and therapeutic approaches. Expert Opin. Investig. Drugs 2005, 14, 567–577. [Google Scholar] [CrossRef]
- Schäfer, A.; Fraccarollo, D.; Werner, L.; Bauersachs, J. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol. Res. 2010, 62, 432–438. [Google Scholar] [CrossRef]
- Heart Failure Society of America. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J. Card. Fail. 2010, 16, 475–539. [CrossRef]
- Dhalla, A.K.; Singal, P.K. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am. J. Physiol. 1994, 266, H1280–H1285. [Google Scholar]
- Hill, M.F.; Singal, P.K. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am. J. Pathol. 1996, 148, 291–300. [Google Scholar]
- Li, R.K.; Sole, M.J.; Mickle, D.A.G.; Schimmer, J.; Goldstein, D. Vitamin E and oxidative stress in the heart of the cardiomyopathic syrian hamster. Free Radic. Biol. Med. 1998, 24, 252–258. [Google Scholar] [CrossRef]
- Freeman, L.M.; Brown, D.J.; Rush, J.E. Assessment of degree of oxidative stress and antioxidant concentrations in dogs with idiopathic dilated cardiomyopathy. J. Am. Vet. Med. Assoc. 1999, 215, 644–646. [Google Scholar]
- de Blois, J.; Simard, S.; Atar, D.; Agewall, S. For the norwegian heart failure registry. COPD predicts mortality in HF: The norwegian heart failure registry. J. Card. Fail. 2010, 16, 225–229. [Google Scholar]
- Jewett, S.L.; Eddy, L.J.; Hochstein, P. Is the autoxidation of catecholamine involved in ischemia-reperfusion injury? Free Radic. Biol. Med. 1989, 6, 185–188. [Google Scholar] [CrossRef]
- Byrne, J.A.; Grieve, D.J.; Cave, A.C.; Shah, A.M. Oxidative stress and heart failure. Arch. Mal. Coeur Vaiss. 2003, 96, 214–221. [Google Scholar]
- Giordano, F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 2005, 115, 500–508. [Google Scholar]
- Heymes, C.; Bendall, J.K.; Ratajczak, P.; Cave, A.C.; Samuel, J.L.; Hasenfuss, G.; Shah, A.M. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll. Cardiol. 2003, 41, 2164–2171. [Google Scholar]
- Li, J.M.; Gall, N.P.; Grieve, D.J.; Chen, M.; Shah, A.M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002, 40, 477–484. [Google Scholar] [CrossRef]
- Stefan, D.; Anker, S.D.; Haehling, S.V. Inflammatory mediators in chronic heart failure: An overview. Heart 2004, 90, 464–470. [Google Scholar] [CrossRef]
- Chang, Y.; Hsiao, G.; Chen, S.H.; Chen, Y.C.; Lin, J.H.; Lin, K.H.; Chou, D.S.; Sheu, J.R. Tetramethylpyrazine suppresses HIF-1alpha, TNF-alpha, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacol. Sin. 2007, 28, 327–333. [Google Scholar] [CrossRef]
- Luo, X.X.; Ogata, H.; Xu, X.; Ishitobi, F. Protective effect of tetramethylpyrazine on ischemic neuronal damage in the gerbil hippocampus. No To Shinkei 1994, 46, 841–846. [Google Scholar]
- Kerckhoven, R.V.; van Veen, T.A.B.; Boomsma, F.; Saxena, P.R.; Schoemaker, R.G. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur. J. Pharmacol. 2000, 397, 113–120. [Google Scholar] [CrossRef]
- Liao, S.L.; Kao, T.K.; Chen, W.Y.; Lin, Y.S.; Chen, S.Y.; Raung, S.L.; Wu, C.W.; Lu, H.C.; Chen, C.J. Tetramethylpyrazine reduces ischemic brain injury in rats. Neurosci. Lett. 2004, 30, 40–45. [Google Scholar]
- Feng, M.G.; Feng, G.H.; Zhou, Q.G. Effects ofmethylhesperidin on coronary, renal and cerebral circulation in dogs (in Chinese). Acta Pharmacol. Sin. 1988, 9, 548–550. [Google Scholar]
- Dai, X.Z.; Bache, R.J. Coronary and systemic haemodynamic effect of tetramethylpyrazine in the dog. J. Cardiovasc. Pharmacol. 1985, 7, 841–849. [Google Scholar] [CrossRef]
- Tuttle, R.S.; Marmelstein, L.; Trad, T.; Reddy, S.; Radley, T. In vitro uterine response to tetramethylpyrazine, the active constituent of chung chong (a traditional Chinese medicine). Am. J. Obstet. Gynecol. 1989, 161, 1319–1323. [Google Scholar]
- Salem, R.; Denault, A.Y.; Couture, P.; Bélisle, S.; Fortier, A.; Guertin, M.-C.; Carrier, M.; Martineau, R. Left ventricular end-diastolic pressure is a predictor of mortality in cardiac surgery independently of left ventricular ejection fraction. Br. J. Anaesth. 2006, 97, 292–297. [Google Scholar] [CrossRef]
- Hohensinner, P.J.; Niessner, A.; Huber, K.; Weyand, C.M.; Wojta, J. Inflammation and cardiac outcome. Curr. Opin. Infect. Dis. 2011, 24, 259–264. [Google Scholar] [CrossRef]
- Diwan, A.; Tran, T.; Misra, A.; Mann, D.L. Inflammatory mediators and the failing heart: A translational approach. Curr. Mol. Med. 2003, 3, 161–182. [Google Scholar] [CrossRef]
- Torre-Amione, G.; Kapadia, S.; Benedict, C.; Oral, H.; Young, J.B.; Mann, D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 1996, 27, 1201–1206. [Google Scholar] [CrossRef]
- Deswal, A.; Petersen, N.J.; Feldman, A.M.; Young, J.B.; White, B.G.; Mann, D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103, 2055–2059. [Google Scholar] [CrossRef]
- Dixon, D.-L.; Griggs, K.M.; Bersten, A.D.; de Pasquale, C.G. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine 2011, 56, 593–599. [Google Scholar] [CrossRef]
- Hori, M.; Nishida, K. Oxidative stress and left ventricular remodeling after myocardial infarction. Cardiovasc. Res. 2009, 81, 457–464. [Google Scholar] [CrossRef]
- Kleinbongard, P.; Heusch, G.; Schulz, R. TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol. Ther. 2010, 127, 295–314. [Google Scholar] [CrossRef]
- Tappe, K.H.; Mohammadzadeh, H.; Khashaveh, S.; Rezapour, B.; Barazesh, A. Prevalence of intestinal parasitic infections among primary school attending students in Barandooz-Chay rural region of Urmia, West Azerbaijan province, Iran in 2008. Afr. J. Microbiol. Res. 2011, 5, 788–791. [Google Scholar]
- Noor, N.A. Anxiolytic action and safety of Kava: Effect on rat brain acetylcholinesterase activity and some serum biochemical parameters. Afr. J. Pharm. Pharmacol. 2010, 4, 823–828. [Google Scholar]
- Sun, M.; Chen, M.; Dawood, F.; Zurawska, U.; Li, J.Y.; Parker, T.; Kassiri, Z.; Kirshenbaum, L.A.; Arnold, M.; Khokha, R.; et al. Tumor necrosis factor-alpha mediates Cardia cre modeling and ventricular dysfunction after pressure overload state. Circulation 2007, 115, 1398–4071. [Google Scholar] [CrossRef]
- Shaw, S.M.; Shah, M.K.; Williams, S.G.; Fildes, J.E. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur. J. Heart Fail. 2009, 11, 113–118. [Google Scholar] [CrossRef]
- Dhalla, A.K.; Singal, P.K. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am. J. Physiol. 1994, 266, H1280–H1285. [Google Scholar]
- Hill, M.F.; Singal, P.K. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am. J. Pathol. 1996, 148, 291–300. [Google Scholar]
- Li, R.K.; Sole, M.J.; Mickle, D.A.G.; Schimmer, J.; Goldstein, D. Vitamin E and oxidative stress in the heart of the cardiomyopathic syrian hamster. Free Radic. Biol. Med. 1998, 24, 252–258. [Google Scholar] [CrossRef]
- Freeman, L.M.; Brown, D.J.; Rush, J.E. Assessment of degree of oxidative stress and antioxidant concentrations in dogs with idiopathic dilated cardiomyopathy. J. Am. Vet. Med. Assoc. 1999, 215, 644–646. [Google Scholar]
- Polidori, M.C.; Stahl, W.; Eichler, O.; Niestroj, N.; Sies, H. Profiles of antioxidants in human plasma. Free Radic. Biol. Med. 2001, 30, 456–462. [Google Scholar] [CrossRef]
- Marin-Garcia, J.; Goldenthal, M.J.; Moe, G.W. Mitochondrial pathology in cardiac failure. Cardiovasc. Res. 2001, 49, 17–26. [Google Scholar] [CrossRef]
- Sawyer, D.B.; Colucci, W.S. Mitochondrial oxidative stress in heart failure. “Oxygen wastage” revisited. Circ. Res. 2000, 86, 119–120. [Google Scholar]
- Gey, K.F.; Moser, U.K.; Jordan, P.; Stähelin, H.B.; Eichholzer, M.; Ludin, E. Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: An epidemiological update with special attention to carotene and vitamin C. Am. J. Clin. Nutr. 1998, 57, 787–797. [Google Scholar]
- Hughes, C.M.; Woodside, J.V.; McGartland, C.; Roberts, M.J.; Nicholls, D.P.; McKeown, P.P. Nutritional intake and oxidative stress in chronic heart failure. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 376–382. [Google Scholar] [CrossRef] [Green Version]
- Olivetti, G.; Abbi, R.; Quaini, F.; Kajstura, J.; Cheng, W.; Nitahara, J.A.; Quaini, E.; Di Loreto, C.; Beltrami, C.A.; Krajewski, S.; et al. Apoptosis in the failing human heart. N. Engl. J. Med. 1997, 336, 1131–1141. [Google Scholar] [CrossRef]
- Jethwani Urmi, N.; Mulla Summaiya, A.; Shah Latika, N. Detection of inducible clindamycin resistance by an automated system in a tertiary care hospital. Afr. J. Microbiol. Res. 2011, 5, 2870–2872. [Google Scholar]
- Dhalla, A.K.; Hill, M.F.; Singal, P.K. Role of oxidative stress in transition of hypertrophy to heart failure. J. Am. Coll. Cardiol. 1996, 28, 506–514. [Google Scholar]
- Singal, P.K.; Dhalla, A.K.; Hill, M.; Thomas, T.P. Endogenous antioxidant changes in the myocardium in response to acute and chronic stress conditions. Mol. Cell. Biochem. 1993, 129, 179–186. [Google Scholar] [CrossRef]
- Lai, C.C.; Peng, M.; Huang, L.; Huang, W.H.; Chiu, T.H. Chronic exposure of neonatal cardiac myocytes to hydrogen peroxide enhances the expression of catalase. J. Mol. Cell. Cardiol. 1996, 28, 1157–1163. [Google Scholar] [CrossRef]
- Sedigheh, A.; Jamal, M.S.; Mahbubeh, S.; Somayeh, K.; Mahmoud, R.-K.; Azadeh, A.; Fatemeh, S. Hypoglycaemic and hypolipidemic effects of pumpkin (Cucurbita pepo L.) on alloxan-induced diabetic rats. Afr. J. Pharm. Pharmacol. 2011, 5, 2620–2626. [Google Scholar]
- Dieterich, S.; Bieligk, U.; Beulich, K.; Hasenfuss, G.; Prestle, J. Gene expression of antioxidative enzymes in the human heart: Increased expression of catalase in the end-stage failing heart. Circulation 2000, 101, 33–39. [Google Scholar] [CrossRef]
- Buege, J.A.; Aust, S.D. Microsomal lipid peroxidation. Methods Enzymol. 1978, 52, 302–310. [Google Scholar] [CrossRef]
- Ellman, G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82, 70–77. [Google Scholar] [CrossRef]
- Misra, H.P.; Fridovich, I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972, 247, 3170–3175. [Google Scholar]
- Chiu, D.T.Y.; Stults, F.H.; Tappel, A.L. Purification and properties of rat lung soluble glutathione peroxidase. Biochim. Biophys. Acta 1976, 445, 558–566. [Google Scholar] [CrossRef]
- Aebi, H. Catalase in vitro. Methods Enzymol. 1984, 105, 121–127. [Google Scholar] [CrossRef]
- Luna, L.C. Manual of Histological Screening Methods of Armed Forces Institute of Pathology; McGraw Hill Book Co.: New York, NY, USA, 1960. [Google Scholar]
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Guo, L.; Wang, A.; Sun, Y.; Xu, C. Evaluation of Antioxidant and Immunity Function of Tetramethylpyrazine Phosphate Tablets in Vivo. Molecules 2012, 17, 5412-5421. https://doi.org/10.3390/molecules17055412
Guo L, Wang A, Sun Y, Xu C. Evaluation of Antioxidant and Immunity Function of Tetramethylpyrazine Phosphate Tablets in Vivo. Molecules. 2012; 17(5):5412-5421. https://doi.org/10.3390/molecules17055412
Chicago/Turabian StyleGuo, Ling, Aihong Wang, Yongle Sun, and Chongen Xu. 2012. "Evaluation of Antioxidant and Immunity Function of Tetramethylpyrazine Phosphate Tablets in Vivo" Molecules 17, no. 5: 5412-5421. https://doi.org/10.3390/molecules17055412